In addition to Δ133p53β expression, other well-established markers of cancer prognosis such as the breast cancer subtypes, TP53 mutation, tumor grade, lymph node metastasis (absence or presence) and tumor size (>20 mm) were, as expected, also associated with cancer patient outcome in our cohort (Figure 1—figures supplement 1D–H). The gene discussed is TP53; the disease is metastatic malignant neoplasm in the lymph nodes.